Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Rituximab and vemurafenib could challenge frontline chemotherapy for HCL

Publish date:: June 26, 2019

Key clinical point: A combination of rituximab and vemurafenib offers a high complete remission rate among patients with relapsed or refractory hairy cell leukemia (HCL).

Major finding: Complete remission was achieved in 96% of evaluable patients who received the combination.

Study details: A phase 2 trial involving 31 patients with relapsed or refractory HCL.

Disclosures: Dr. Tiacci reported financial relationships with Roche, AbbVie, and Shire.

Citation:

Tiacci E et al. EHA Congress, Abstract S104.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in B Cell Lymphoma

Four-item prognostic index predicts survival in adult Burkitt lymphoma,

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

ZUMA-12 study shows frontline axi-cel has substantial activity in high-risk large B-cell lymphoma,

Pediatric regimens better for adolescents/young adults with aggressive B-cell NHL,

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL,